Beyond CAR-T: Multi-layered engineering strategies shaping the next generation of cellular cancer immunotherapy
Annals of Hematology · 15.08.2026 · 105 (12)
DOI: 10.1007/s00277-026-07243-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Hematology, online erschienen am 15.08.2026. Verfasst von Yunqi Jiang und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Changzhou University, Changzhou, 213000, China. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Neoplasms, Receptors, Chimeric Antigen, Cell Engineering. Die Arbeit nennt 246 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Adoptive cellular immunotherapy has transformed the treatment landscape for hematologic malignancies; however, its broader application to solid tumors remains limited by antigen heterogeneity, inadequate persistence, restricted tumor infiltration, and the profoundly immunosuppressive tumor microenvironment (TME). While conventional CAR-T cell therapy has demonstrated remarkable clinical success, no single immune-cell platform is likely to overcome all biological barriers encountered in complex solid tumors. Emerging evidence instead supports a shift toward an integrated cellular immunotherapy ecosystem that combines the complementary strengths of multiple engineered immune cell populations. In this review, we present a unifying framework for the multi-layered engineering of next-generation immune cell therapies, encompassing CAR-natural killer (CAR-NK) cells, TCR-engineered αβ T cells, γδ T cells, CAR-natural killer T (CAR-NKT) cells, and CAR-macrophages. Rather than considering these platforms as isolated technologies, we examine how shared engineering strategies, including cytokine armoring, CRISPR-based genome editing, protein-level receptor optimization, tumor-responsive gene circuits, metabolic reprogramming, and induced pluripotent stem cell (iPSC)-based manufacturing, can be integrated to enhance persistence, functionality, safety, and resistance to TME-mediated suppression. We further discuss the biological rationale, preclinical advances, and emerging clinical evidence supporting each platform, highlighting their distinct and complementary mechanisms of tumor recognition and immune activation. Finally, we propose that the future of cancer immunotherapy lies not in the optimization of a single cellular modality, but in the development of synergistic, scalable, and off-the-shelf engineered immune-cell networks capable of delivering durable and effective responses against heterogeneous solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Changzhou University, Changzhou, 213000, China.
- Shiraz University of Medical Sciences, Shiraz, Iran. ashamehrabi88@gmail.com.
Zitieren
APA
Jiang, Y., Zhang, S., & Arami, S. (2026). Beyond CAR-T: Multi-layered engineering strategies shaping the next generation of cellular cancer immunotherapy. Annals of Hematology, 105(12). https://doi.org/10.1007/s00277-026-07243-2
Vancouver
Jiang Y, Zhang S, Arami S. Beyond CAR-T: Multi-layered engineering strategies shaping the next generation of cellular cancer immunotherapy. Annals of Hematology. 2026;105(12). doi:10.1007/s00277-026-07243-2
BibTeX
@article{Jiang2026,
author = {Jiang, Yunqi and Zhang, Sai and Arami, Sharareh},
title = {Beyond CAR-T: Multi-layered engineering strategies shaping the next generation of cellular cancer immunotherapy},
journal = {Annals of Hematology},
year = {2026},
volume = {105},
number = {12},
doi = {10.1007/s00277-026-07243-2}
}
EUVIMED